Horizon Therapeutics to make blockbuster out of Genmab drug in 2021

Tepezza can already boast one of the best launches ever for a rare disease drug, and current owner company Horizon Therapeutics forecasts that the drug, developed in Genmab's labs, will sell for more than a billion US dollars in 2021.

Photo: PR / Genmab

US-based biopharmaceutical company Horizon Therapeutics is pulling out the big guns to market its rare disease drug, Tepezza, originally developed in the laboratories of Danish biotech firm Genmab.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs